[Pharmacologic treatment of patent ductus arteriosus in premature infants].
Sixty-one preterm infants (birthweight, 1.529 +/- 450g; gestational age, 31,9 +/- 2,4 weeks) developed a large DAP. Seventy-eight per cent required mechanical ventilation and 75,5% had hyaline membrane disease. Pharmacological closure of the DAP with oral indomethacin was attempted on 31. A steady improvement was achieved in 64,5%. The postnatal age of responders was lower than that of non-responders. Neonatal survival was over 90% but long-term survival dropped to 64,5% linked to a high incidence of bronchopulmonary dysplasia. The patients with bronchopulmonary dysplasia had received indomethacin later than the others. It was found that postnatal age at the time of indomethacin administration correlated with the days of mechanical ventilation later required by the survivors.
D000367:Age Factors; D004231:Diuresis / Q000187:drug effects; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use*; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy*
D007213:Indomethacin
Tratamiento farmacológico del ductus arterioso persistente en el recién nacido pretérmino.